Thomas John Clinical Oncology Society of Australia Annual Scientific Meeting 2020

Abstracts this author is presenting:

• Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumour resection: ADAURA — Best of the Best Orals - Clinical Research